Benitec Biopharma Inc 2026年季度报告

(Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934For the quarterly period ended March 31, 2026☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934For the transition period fromtoCommission File Number 001-39267 BENITEC BIOPHARMA INC. (Exact name of registrant as specified in its charter) 3940 Trust Way, Hayward, California 94545(Address of principal executive offices & zip code)(510) 780-0819(Registrant’s telephone number, including area code) Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file suchreports), and (2) has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period thatthe registrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒Emerging growth company☐ Accelerated filer☐ Smaller reporting company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐or No☒We had 34,354,334 shares of our common stock outstanding as of the close of business on May 4, 2026. BENITEC BIOPHARMA INC. INDEX TO FORM 10-Q SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS3PART I—FINANCIAL INFORMATION5ITEM 1.Financial Statements5Consolidated Balance Sheets as of March 31, 2026 (Unaudited) and June 30, 20255Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended March 31,2026 and 2025 (Unaudited)6Consolidated Statements of Stockholders’ Equity for the Three and Nine Months Ended March 31, 2026 and 2025(Unaudited)7Consolidated Statements of Cash Flows for the Nine Months Ended March 31, 2026 and 2025 (Unaudited)8Notes to Consolidated Financial Statements (Unaudited)9ITEM 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations23ITEM 3.Quantitative and Qualitative Disclosures About Market Risk35ITEM 4.Controls and Procedures35PART II—OTHER INFORMATIONITEM 1.Legal Proceedings37ITEM 1A.Risk Factors37ITEM 2.Unregistered Sales of Equity Securities and Use of Proceeds37ITEM 3.Defaults Upon Senior Securities37ITEM 4.Mine Safety Disclosures37ITEM 5.Other Information37ITEM 6.Exhibits38SIGNATURES39 This Report contains forward-looking statementswithin the meaning of the federal securities laws that are subject to a number ofrisks and uncertainties, many of which are beyond our control. Our forward-looking statements relate to future events or our futureperformance and include, but are not limited to, statements concerning our business strategy, future commercial revenues, marketgrowth, capital requirements, new product introductions, expansion plans and the adequacy of our funding. All statements, otherthan statements of historical fact included in this Report, are forward-looking statements. When used in this Report, the words“could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “continue,” “predict,” “potential,” “project,” or the negativeof these terms, and similar expressions, are intended to identify forward-looking statements, although not all forward-lookingstatements contain such identifying words. These statements involve known and unknown risks, uncertainties and other importantfactors that may cause our actual results, levels of activity, performance or achievements to be materially different from theinformation expressed or implied by these forward-looking statements. Some of the risks and uncertainties that may cause our actual results, performance or achievements to differ materially from thoseexpressed or implied by forward-looking statements include the following: •the success of our plans to develop and potentially commercialize our product candidates;•the timing of the completion of preclinical studies and clinical trials;•the timing and sufficiency of patient enrollment and dosing in any future clinical trials;•the timing of the availability of data from our clinical trials;